培美曲塞联合奈达铂二线治疗肺腺癌临床观察  

Clinical observation of Pemetrexed combined Nedaplatin as second-line treatment for lung adenocarcinoma

作　　者：郭刚[1] 陈楠[1] 李高峰[1] 王德光[1] 张继朋[1] 陈瑞彬[1] 

机构地区：[1]昆明医学院第三附属医院胸外科,云南昆明650000

出　　处：《实用临床医药杂志》2011年第19期105-107,共3页Journal of Clinical Medicine in Practice

基　　金：云南省社会发展重点项目(2010CA015);云南省科技厅联合基金项目(2010CD185)

摘　　要：目的评价培美曲塞联合奈达铂二线治疗肺腺癌的疗效及不良反应。方法收集晚期肺腺癌患者34例,既往接受一线接受化疗失败28例,曾行EGFR-TKI治疗后病情进展6例;给予2个周期以上培美曲塞(500 mg/m2,d1)联合奈达铂(80 mg/m2,d1)治疗,21 d为1周期。结果 34例患者完全缓解(CR)0例、部分缓解(PR)5例、稳定(SD)16例、进展(PD)13例,有效率(RR)为14.7%;中位生存时间10.4月,1年生存率44.1%。结论培美曲塞联合奈达铂二线治疗肺腺癌疗效好、可改善患者生活质量、毒性反应轻,对于分子靶向药物耐受的患者有一定疗效。Objective To evaluate the curative effect and adverse reaction of Pemetrexed plus Nedaplatin as second -line treatment for lung adenocarcinoma. Methods Thirty -four cases of advanced non - small - cell lung cancer patients were selected, 28 cases who accepted a line chemotherapy failed, 6 patients had received the EGFR - TKI treatment. All patients were performed 2 cycle above Pemetrexed （500 mg/m2, d1 ） and Nedaplatin （80 mg/m2, d1 ）. Results The overall response rate in the group was 14.7% , No patient had complete response （CR） , 5 patients had partial response （ PR）, 16 patients had SD and 13 patients had PD. The 1 - year survival rate was 44.1%. The median survival time was 10.4 months. Conclusion Pemetrexed combined with Nedaplatin as second - line treatment for lung adenocarcinoma can provide patients with good curative effect, quality of life, and less toxicity reactions. It also has certain curative effect for patients with molecular targeted drug resistance.

关 键 词：培美曲塞 奈达铂 肺腺癌 二线治疗 

分 类 号：R734.2[医药卫生—肿瘤]